BenevolentAI S.A. (BAI.AS)

EUR 0.4

(-4.31%)

Market Cap (In EUR)

52.39 Million

Revenue (In EUR)

7.33 Million

Net Income (In EUR)

-63.31 Million

Avg. Volume

45.29 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.36-2.66
PE
-
EPS
-
Beta Value
0.888
ISIN
LU2355630455
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Joerg Moeller M.D., Ph.D.
Employee Count
-
Website
https://www.benevolent.com
Ipo Date
2022-04-25
Details
BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.